BenzingaDoubao · 实盘不做把握 5/10不做原因:无增量信息
北京时间·🕒 发布 00:11:42·⟳ 抓取 00:11:57 +15s·⚡ 决策 10-28 00:13:29 +1m32s·2.7 小时前
Centene Q3利润超预期并上调2026全年指引，股价盘中涨约2.4%逼近52周高点
本条为当日盘前已发布Q3财报的盘中媒体复述，核心数字（EPS $0.58、收入$506.5亿、上调全年指引）与已处理记录完全一致，无新增金额或指引修正；股价已从盘前-2.7%（低见$62.55）反转至盘中+2.4%逼近52周高点，且预期差口径矛盾、会员大幅收缩，多空均无可靠edge。
📄 原文Benzinga↗ 原文
Centene Stock Approaches 52-Week High on Faster-Than-Expected Earnings Recovery
U.S. health care insurance provider Centene Corporation (NYSE:CNC) reported better-than-expected third-quarter earnings…
不做 Centene Corporation（CNC.US）
同一Q3财报事件当日已研判、本条无新增事实；股价已自盘前-2.7%深V反转至盘中+2.4%并逼近52周高点$72.50，重定价基本完成，叠加EPS预期差口径矛盾、会员大幅收缩与GAAP亏损，追高与做空均无可靠edge，不做
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Centene Q3利润超预期并上调全年指引，方向正面，但同一财报当日已被研判、本条无新增信息，股价盘中已完成反转重定价至年内高位附近，追高风险回报不划算，不做。
🔎 新鲜度:最早出现 2026-10-27 · 扩散 high · price-in 风险 high ↗
关键理由
- 调整后EPS与收入超预期、全年EPS指引上调至>$5.20且MA提前一年盈亏平衡，基本面修复方向明确
- HBR环比改善30bp、PDP利润率强劲，管理层对2026收尾及2027利润率扩张表态积极
主要风险
- 总会员一年减少约227万、Marketplace会员近乎腰斩，全年会员预计降8%–9%，收入增长质量与2027 MA会员下滑构成压制
- EPS一致预期口径互相矛盾且公司当季GAAP每股亏损$0.14，真实预期差存疑；股价已自盘前深V拉回逼近52周高点，盘中追高易在高位接盘
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-10-27 · 影响 weakens
本事件文本即显示GAAP每股亏损$0.14、商业/Marketplace收入与会员大幅下滑、2027 MA会员预计同比下降，削弱超预期的盈利质量
检索:Centene Q3 2026 GAAP loss membership decline Marketplace Medicare Advantage 2027 - 做多前查反向 · 来源 web · 日期 2026-10-27 · 影响 weakens
已处理记录显示GuruFocus同日称$0.58低于分析师预期，与Benzinga/Investing称大超预期矛盾，真实预期差不可靠
检索:Centene EPS consensus 0.58 miss vs beat GuruFocus
先例如何影响了这次决策
对本次决策的影响:结论由重复事件去重、当日盘中已反转重定价及预期差口径矛盾主导，不依赖先例；缺乏新edge故不做
方向:未检索外部同类保险股财报先例
涨幅量级:无足够高相似对齐样本校准幅度
形态:无先例支撑见光死判断
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 602 ms
{"result": "search_processed_events:agent query=`centene cnc q3 2026 earnings beat adjusted eps guidance raised | centene medicare advantage break-even 2026 earnings recovery | centene 三季度财报 上调2026全年指引 medicaid hbr`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 61.8/72 小时、6829 条本臂决策(完整)，返回 1 条候选。\n• 10-27 12:19 UTC(北京 2 - stock_quote 成功 stock_tools HTTP · 3,764 ms
{
原文全文
展开原文 · 2,392 字
U.S. health care insurance provider Centene Corporation (NYSE:CNC) reported better-than-expected third-quarter earnings, with adjusted earnings of 58 cents, beating the consensus of 10 cents per share.
Centene’s sales reached $50.647 billion, exceeding the consensus estimate of $47.114 billion.
“Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated,” said Centene CEO Sarah London.
“We remain focused on a strong finish to 2026 and building on this progress in 2027,” London added.
Health Benefits Ratio and Core Margin Trends
The health benefits ratio (HBR) was 92.7% for the third quarter of 2026, improving sequentially by 30 basis points from the second quarter, and the company said it is keeping pace with the trajectory to achieve a full-year Medicaid HBR of 93.5.
Membership Contraction
Total membership across Centene’s portfolio declined to 25.698 million from 27.968 million a year ago.
Medicaid membership fell from 12.706 million to 11.895 million, while Marketplace fell from 5.828 million to 3.403 million.
CFO Drew Asher said, “We ended Q3 with 11.9 million members, down 5% year to date, and we expect some states to continue to trim Medicaid rolls leading up to OB3 implementation in 2027. So we are holding our full-year view of membership down 8% to 9%…”
Asher added, “…forecasting to reach Medicare Advantage break-even in 2026, a year earlier than our multi-year plan, and PDP continues to perform strongly with the 2026 forecasted pre-tax margin in the mid to high 3s zone.”
Centene Lifts 2026 Guidance
During an earnings conference call, London said, “We expect Medicare Advantage membership to be down year over year in 2027 as we construct a footprint that will allow us margin expansion in 2027…”
Centene expects fiscal 2026 adjusted earnings of more than $5.20 per share versus Wall Street consensus of $4.88.
The company raised its 2026 sales guidance from $193.50 billion-$197.50 billion to $196.50 billion-$200.50 billion versus analyst estimate of $196.334 billion.
CNC Price Action: Centene shares were up 2.75% at $69.90 at the time of publication on Tuesday. The stock is approaching its 52-week high of $72.50, according to Benzinga Pro data.
Photo by JHVEPhoto via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Centene’s sales reached $50.647 billion, exceeding the consensus estimate of $47.114 billion.
“Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated,” said Centene CEO Sarah London.
“We remain focused on a strong finish to 2026 and building on this progress in 2027,” London added.
Health Benefits Ratio and Core Margin Trends
The health benefits ratio (HBR) was 92.7% for the third quarter of 2026, improving sequentially by 30 basis points from the second quarter, and the company said it is keeping pace with the trajectory to achieve a full-year Medicaid HBR of 93.5.
Membership Contraction
Total membership across Centene’s portfolio declined to 25.698 million from 27.968 million a year ago.
Medicaid membership fell from 12.706 million to 11.895 million, while Marketplace fell from 5.828 million to 3.403 million.
CFO Drew Asher said, “We ended Q3 with 11.9 million members, down 5% year to date, and we expect some states to continue to trim Medicaid rolls leading up to OB3 implementation in 2027. So we are holding our full-year view of membership down 8% to 9%…”
Asher added, “…forecasting to reach Medicare Advantage break-even in 2026, a year earlier than our multi-year plan, and PDP continues to perform strongly with the 2026 forecasted pre-tax margin in the mid to high 3s zone.”
Centene Lifts 2026 Guidance
During an earnings conference call, London said, “We expect Medicare Advantage membership to be down year over year in 2027 as we construct a footprint that will allow us margin expansion in 2027…”
Centene expects fiscal 2026 adjusted earnings of more than $5.20 per share versus Wall Street consensus of $4.88.
The company raised its 2026 sales guidance from $193.50 billion-$197.50 billion to $196.50 billion-$200.50 billion versus analyst estimate of $196.334 billion.
CNC Price Action: Centene shares were up 2.75% at $69.90 at the time of publication on Tuesday. The stock is approaching its 52-week high of $72.50, according to Benzinga Pro data.
Photo by JHVEPhoto via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
05d8c4415d· 2026-10-28 00:13 · doubao / doubao-seed-evolving-latest-version · 策略包2cd9474a9f7b当前